Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.64 |
| ▸ | GNRHR | P30968 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL7516281 | 1.00 | GNRHR (0.76) | GNRHRMEN1KMT2A | |
| SCHEMBL6544690 | 0.96 | GNRHR (0.81) | GNRHRMEN1KMT2A | |
| Oxalic Acid SCHEMBL7524227 | 0.96 | GNRHR (0.80) | GNRHRMEN1KMT2A | |
| Malonic Acid SCHEMBL7525788 | 0.94 | GNRHR (0.79) | GNRHRMEN1KMT2A | |
| Succinic Acid SCHEMBL7525336 | 0.94 | GNRHR (0.77) | GNRHRMEN1KMT2A | |
| SCHEMBL7523063 | 0.93 | GNRHR (0.78) | GNRHRMEN1KMT2A | |
| SCHEMBL7011239 | 0.91 | GNRHR (0.84) | GNRHRMEN1KMT2A | |
| Malic Acid SCHEMBL7529453 | 0.90 | GNRHR (0.72) | GNRHRMEN1KMT2A | |
| SCHEMBL8160999 | 0.90 | GNRHR (0.82) | GNRHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7503209 | 0.89 | GNRHR (0.81) | GNRHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198384-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6437132-B2 | INHIBITOR OF GONADOTROPIN RELEASING HORMONE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019529-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-02-14 | — | — | US | disclosed |
| US-6313301-B1 | CYCLIZATION; LUTEINIZING HORMONE RELEASING HORMONE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1004585-A1 | THIENOPYRIDINE DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESS FOR PRODUCING THE BOTH | Takeda Chemical Industries, Ltd. (JP) | 2000-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198384-A1 | Thienopyridine derivatives, their intermediates and production thereof | GNRHR, KISS1R, CYP19A1 | MEN1 1739/4885KMT2A 1900/4885GNRHR 1/4885 |
| US-20020019529-A1 | Thienopyridine derivatives, their intermediates and production thereof | GNRHR, KISS1R, CYP19A1 | MEN1 1739/4885KMT2A 1900/4885GNRHR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.